Wednesday, November 13, 2013, 11:00 a.m. - 11:55a.m., Room 405
The establishment of China’s first national organization against rare diseases, China Rare Diseases Prevention & Treatment Alliance, reaffirms the country’s commitment to innovative health care research. China is actively promoting the regulation of rare diseases and orphan drugs. This panel will focus on the research and development of such drugs in China, and key leaders will discuss how they expect this field to develop.
Jeff Stevens, Managing Director & Partner, L.E.K. Consulting
Ko-Chung Lin, PhD, Founder & CEO, Pharmaessentia
Jerry Zeldis, MD, PhD, Chief Executive Officer, Celgene Global Health and Chief Medical Officer, Celgene Corporation
Lit-Fui Lau, PhD, General Manager, Lee's Pharmaceutical Holding Limited